Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras converting CAAX endopeptidase 1 (RCE1) is an integral membrane enzyme located in the endoplasmic reticulum that functions as an intramembrane metalloproteinase. It cleaves the C-terminal tripeptide ("-AAX") from prenylated proteins containing a CAAX motif, including the Ras family of small GTPases, nuclear lamins, and various protein kinases and phosphatases. This post-translational modification is essential for correct localization and function of these proteins, many of which are involved in key cellular signaling pathways. Disruption of RCE1 activity affects multiple signaling proteins and has been linked to cancer and other diseases, making RCE1 a potential therapeutic target under active investigation[1][2][3][5].
Inhibition of RCE1 disrupts cleavage of CAAX motif, leading to mislocalization and impaired function of Ras and other prenylated proteins
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras converting CAAX endopeptidase 1 (RCE1).